ZM014

About Zumutor Biologics

Zumutor Biologics is a private, pre-revenue biotechnology company advancing a pipeline of novel NK cell-targeting immunotherapies. Its lead asset, ZM008, is a first-in-class anti-LLT1 antibody currently in Phase 1 clinical trials for solid tumors, representing a key clinical validation point for its platform. The company leverages a dual geographic strategy with operations in the US and India, and is backed by venture capital investors including Accel Partners and IDG Ventures.

Therapeutic Areas

Other Lymphoma Drugs